Inspire Medical Systems, Inc. $INSP Shares Purchased by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in Inspire Medical Systems by 39.2% during the 1st quarter, now holding 18,687 shares valued at approximately $2.976 million.
• Inspire Medical Systems reported earnings of $0.45 EPS, surpassing expectations, with revenue of $217.09 million for the quarter, reflecting a 10.8% year-over-year growth.
• The company initiated a stock buyback program allowing the repurchase of up to $200 million in shares, indicating the board's belief that the stock is currently undervalued.

B. Metzler seel. Sohn & Co. AG increased its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 39.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,687 shares of the company's stock after acquiring an additional 5,262 shares during the quarter. B. Metzler seel. Sohn & Co. AG owned approximately 0.06% of Inspire Medical Systems worth $2,976,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its position in shares of Inspire Medical Systems by 356.5% in the first quarter. Parallel Advisors LLC now owns 210 shares of the company's stock valued at $33,000 after purchasing an additional 164 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Inspire Medical Systems by 27.2% during the first quarter. Smartleaf Asset Management LLC now owns 454 shares of the company's stock valued at $71,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Inspire Medical Systems by 253.7% in the first quarter. GAMMA Investing LLC now owns 573 shares of the company's stock valued at $91,000 after acquiring an additional 411 shares in the last quarter. Archer Investment Corp purchased a new position in shares of Inspire Medical Systems in the first quarter valued at approximately $96,000. Finally, AlphaQuest LLC lifted its holdings in Inspire Medical Systems by 248.5% in the 1st quarter. AlphaQuest LLC now owns 1,028 shares of the company's stock valued at $164,000 after purchasing an additional 733 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Performance

Shares of INSP traded up $0.14 during midday trading on Tuesday, hitting $93.83. 426,394 shares of the stock were exchanged, compared to its average volume of 686,044. The firm has a market cap of $2.77 billion, a P/E ratio of 54.23, a P/E/G ratio of 2.92 and a beta of 1.15. Inspire Medical Systems, Inc. has a 52-week low of $73.92 and a 52-week high of $225.00. The stock has a fifty day simple moving average of $113.14 and a 200 day simple moving average of $140.38.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.22 by $0.23. The business had revenue of $217.09 million during the quarter, compared to the consensus estimate of $214.50 million. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The company's quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, equities research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems declared that its Board of Directors has initiated a share repurchase program on Monday, August 11th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to reacquire up to 8.6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. KeyCorp lowered shares of Inspire Medical Systems from an "overweight" rating to a "sector weight" rating in a report on Tuesday, August 5th. Piper Sandler decreased their target price on shares of Inspire Medical Systems from $233.00 to $150.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. Wells Fargo & Company dropped their price target on Inspire Medical Systems from $174.00 to $101.00 and set an "equal weight" rating for the company in a research report on Tuesday, August 5th. Wall Street Zen downgraded Inspire Medical Systems from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. Finally, UBS Group set a $230.00 target price on Inspire Medical Systems and gave the company a "buy" rating in a report on Tuesday, August 5th. Eight analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $164.50.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.